Every 8-K that LivaNova PLC (LIVN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow LIVN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LIVN filings page.
LivaNova PLC reported second‑quarter 2026 results with net revenue of $390.6 million, up 10.8% on a reported basis and 9.8% at constant currency versus 2025. Cardiopulmonary revenue rose to $221.6 million and Neuromodulation to $166.9 million, both delivering double‑digit growth.
GAAP net income was $108.6 million (diluted EPS $1.93) compared with $27.2 million ($0.50) a year earlier and included a discrete tax benefit of €81.8 million ($95.4 million) from a favorable Italian ruling on the SNIA environmental liability. Adjusted diluted EPS increased to $1.26 from $1.05, and adjusted operating income rose to $90.8 million from $77.4 million. Net cash from operating activities was $66.6 million, with adjusted free cash flow of $45.5 million.
LivaNova raised 2026 constant‑currency revenue growth guidance to 8%–9% and adjusted diluted EPS guidance to $4.30–$4.40, while lowering adjusted free cash flow guidance to $140–$160 million to fund Cardiopulmonary capacity, innovation, and IT investments. The company also announced a long‑term oxygenator‑component supply agreement with Thermo Fisher Scientific and several senior leadership appointments.
LivaNova PLC reported the results of its 2026 Annual General Meeting, where shareholders approved all 10 proposals presented. Eleven directors were re-elected for terms running until the 2027 AGM, maintaining continuity on the board.
Shareholders gave advisory approval to the U.S. say-on-pay vote for named executive officers and to the UK directors’ remuneration report. They also ratified PricewaterhouseCoopers LLP as both the U.S. independent registered public accounting firm and the UK statutory auditor for 2026 and authorized the board or Audit and Compliance Committee to set the UK auditor’s fees.
Investors renewed authority for directors to allot shares up to a nominal £10,985,296 and to disapply pre-emption rights on the same nominal amount. They also approved share repurchase contracts allowing buybacks of up to 10% of total issued ordinary shares as of April 13, 2026.
LivaNova PLC reported strong first-quarter 2026 results and raised its full-year outlook. Q1 net revenue was $362.3 million, up 14.3% year over year (11.1% on a constant-currency basis), led by Cardiopulmonary and Neuromodulation growth across all regions.
U.S. GAAP diluted EPS was $0.40 versus a prior-year diluted loss per share of $6.01, which had included a large SNIA environmental charge. Adjusted diluted EPS rose to $0.98 from $0.88. The company generated $15.2 million of net cash from operating activities and $3.8 million of adjusted free cash flow.
LivaNova now expects 2026 revenue to grow 7.0%–8.0% on a constant-currency basis and adjusted diluted EPS of $4.20–$4.30, while maintaining adjusted free cash flow guidance of $160–$180 million. The company also received FDA premarket approval for its aura6000 system for moderate to severe obstructive sleep apnea, positioning it for entry into the OSA market.
LivaNova PLC reported strong fourth-quarter and full-year 2025 results while absorbing a large environmental charge and issuing 2026 guidance. Q4 revenue was $360.9 million, up 12.1% on a reported basis and 9.5% in constant currency, with double‑digit growth in both Cardiopulmonary and Neuromodulation.
For 2025, revenue reached $1.39 billion, rising 10.7% reported and 10.7% organically. GAAP diluted loss per share was $4.45 due largely to a $365.6 million SNIA environmental liability, while adjusted diluted earnings per share increased to $3.90 from $3.38.
The company guided 2026 constant-currency revenue growth between 6.0% and 7.0%, adjusted diluted earnings per share of $4.15 to $4.25, and adjusted free cash flow of $160 million to $180 million. LivaNova also gained significantly higher Medicare reimbursement for VNS Therapy DRE procedures and received U.S. FDA approval for its cloud-based digital health platform, supporting future Neuromodulation growth.
LivaNova PLC reported a leadership change in its legal function. On January 12, 2026, Senior Vice President, Chief Legal Officer, and Company Secretary Michael Hutchinson notified the company that he is resigning to pursue another opportunity. His last day with LivaNova will be January 26, 2026, creating a near-term transition period for the company’s legal and governance roles.
The company plans to retain an external search firm to begin the process of finding a new Chief Legal Officer, indicating that the board and management aim to bring in a successor through a structured, formal search.
LivaNova PLC furnished an 8-K announcing financial results for the quarter ended September 30, 2025. The company will host a business update conference call and webcast on November 5, 2025, at 1 p.m. London time (8 a.m. Eastern Time), accessible via its events page.
The related press release is attached as Exhibit 99.1 and, under Item 2.02, is being furnished and not deemed filed under the Exchange Act.
LivaNova PLC reported that its Board of Directors appointed Donald Zurbay as a director and member of the Audit and Compliance Committee, effective September 4, 2025. He brings more than 20 years of leadership experience in healthcare, including serving as President, Chief Executive Officer and director of Patterson Companies, Inc. from October 2022 to May 2025, and previously as its Chief Financial Officer from June 2018 to October 2022. He also held senior finance roles at St. Jude Medical, Inc., including Chief Financial Officer.
As a non-executive director, Zurbay will be compensated under LivaNova’s Remuneration Policy, including an annual board retainer of $70,000, an Audit and Compliance Committee member fee of $15,000, and an annual service-based restricted stock award valued at $185,000, all prorated until the 2026 Annual General Meeting. The company states there is no special arrangement leading to his selection and no related-party transactions requiring disclosure.